MX2014015715A - Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders. - Google Patents

Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.

Info

Publication number
MX2014015715A
MX2014015715A MX2014015715A MX2014015715A MX2014015715A MX 2014015715 A MX2014015715 A MX 2014015715A MX 2014015715 A MX2014015715 A MX 2014015715A MX 2014015715 A MX2014015715 A MX 2014015715A MX 2014015715 A MX2014015715 A MX 2014015715A
Authority
MX
Mexico
Prior art keywords
masp
inhibitory agent
disease
compositions
subject
Prior art date
Application number
MX2014015715A
Other languages
Spanish (es)
Inventor
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Thomas Dudler
Patrick Gray
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014015715(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2014015715A publication Critical patent/MX2014015715A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

In one aspect, the invention provides methods and compositions for inhibiting MASP-3 -dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3 -dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
MX2014015715A 2012-06-18 2013-06-18 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders. MX2014015715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661167P 2012-06-18 2012-06-18
PCT/US2013/046432 WO2013192240A2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders

Publications (1)

Publication Number Publication Date
MX2014015715A true MX2014015715A (en) 2016-02-05

Family

ID=49769678

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014015715A MX2014015715A (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.
MX2020005700A MX2020005700A (en) 2012-06-18 2014-12-17 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.
MX2019012909A MX2019012909A (en) 2012-06-18 2014-12-17 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020005700A MX2020005700A (en) 2012-06-18 2014-12-17 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.
MX2019012909A MX2019012909A (en) 2012-06-18 2014-12-17 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.

Country Status (27)

Country Link
US (3) US20130344073A1 (en)
EP (4) EP4119577A3 (en)
JP (4) JP6445972B2 (en)
KR (4) KR102339315B1 (en)
CN (3) CN115040653A (en)
AU (3) AU2013277309B2 (en)
BR (1) BR112014031522A2 (en)
CA (2) CA3214532A1 (en)
CL (2) CL2014003455A1 (en)
CY (1) CY1124234T1 (en)
DK (1) DK2861246T3 (en)
ES (1) ES2864857T3 (en)
HK (1) HK1209623A1 (en)
HR (1) HRP20210559T1 (en)
HU (1) HUE053727T2 (en)
IL (2) IL236327B (en)
IN (1) IN2015KN00015A (en)
LT (1) LT2861246T (en)
MX (3) MX2014015715A (en)
NZ (1) NZ629473A (en)
PL (1) PL2861246T3 (en)
PT (1) PT2861246T (en)
RS (1) RS61755B1 (en)
RU (2) RU2709351C2 (en)
SI (1) SI2861246T1 (en)
WO (1) WO2013192240A2 (en)
ZA (1) ZA201500094B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
RU2662563C2 (en) 2011-04-08 2018-07-26 Юниверсити Оф Лестер Methods for treating conditions associated with masp-2 dependent complement activation
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
ES2964340T3 (en) 2013-03-15 2024-04-05 Omeros Corp Methods for generating antibodies carrying bioactive peptides and compositions comprising the same
KR102318483B1 (en) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Fc region variant
EP2983710B1 (en) * 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
EP3632467B1 (en) 2013-06-07 2023-09-27 Duke University Inhibitors of complement factor h
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
HUE051746T2 (en) 2013-10-17 2021-03-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
EP3151845A4 (en) * 2014-06-05 2018-01-17 The Regents of the University of Colorado, a body corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
EP3215527A4 (en) 2014-11-05 2018-04-18 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
JP2018516083A (en) * 2015-06-03 2018-06-21 コイン サイエンティフィック、 エルエルシー Method for establishing threshold limits for chemical or biological agents in target species
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3373963A4 (en) 2015-11-09 2019-07-10 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
SG11201803703UA (en) 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
KR102564616B1 (en) * 2016-01-05 2023-08-08 유니버시티 오브 레스터 Methods for inhibiting fibrosis in a subject in need thereof
CA3096270C (en) * 2016-03-31 2024-05-21 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170154B1 (en) * 2016-08-01 2023-03-28 Omeros Corp Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
JOP20170170B1 (en) 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
ES2933513T3 (en) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Macrocyclic compounds for the treatment of medical disorders
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3606965A4 (en) 2017-04-03 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
MA49960A (en) * 2017-08-25 2021-06-02 Omeros Corp HIGH CONCENTRATED, LOW VISCOSITY MASP-2 INHIBITOR ANTIBODY FORMULATIONS, KITS AND METHODS OF TREATMENT OF SUBJECTS WITH ATYPICAL HEMOLYTIC SYNDROME
MX2020010528A (en) * 2018-04-13 2020-11-06 Chugai Pharmaceutical Co Ltd Anti-complement component antibodies and methods of use.
CN112638417A (en) * 2018-06-22 2021-04-09 奥默罗斯公司 Compositions and methods for inhibiting MASP-2 for the treatment of various thrombotic diseases and disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP3966226A1 (en) * 2019-05-07 2022-03-16 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
BR112022010895A2 (en) 2019-12-04 2022-09-06 Omeros Corp COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD FOR TREATMENT A DISEASE OR DISORDER ASSOCIATED WITH SERINE PROTEASE-2 ASSOCIATED WITH MANAN-BINDING LECTIN
CA3159167A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
CN115052604A (en) 2019-12-04 2022-09-13 奥默罗斯公司 MASP-2 inhibitors and methods of use
CA3159159A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
CN112237630A (en) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 Application of substance aiming at MASP-2, coronavirus N protein or combination thereof in preparation of drugs for diseases caused by coronaviruses
TW202319069A (en) * 2020-03-06 2023-05-16 美商奥默羅斯公司 Methods of inhibiting masp-2 for the treatment and/or prevention of acute respiratory distress syndrome, pneumonia or some other pulmonary manifestation of influenza virus infection induced by influenza virus
CN115215937B (en) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
CN114989259B (en) * 2022-05-27 2023-06-09 成都佩德生物医药有限公司 Small molecule peptide Ped4 and application thereof
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ATE149841T1 (en) 1990-01-26 1997-03-15 Immunomedics Inc VACCINES AGAINST CANCER AND INFECTIOUS DISEASES
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
JP2003515338A (en) * 1999-12-02 2003-05-07 クリスチャン イェンセニウス，イェンス Complement-binding enzyme, MASP-3, and uses thereof
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
WO2003077937A1 (en) * 2002-03-15 2003-09-25 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
MXPA05008570A (en) * 2003-02-21 2005-11-04 Tanox Inc Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury.
DE602004031836D1 (en) * 2003-07-08 2011-04-28 Umc Utrecht Holding Bv THERAPEUTIC USE OF LPI, AN INHIBITOR OF THE LECTIN PATH IN STAPHYLOKOCKS IN INFLAMMATORY DISEASES
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2457585A1 (en) * 2004-06-10 2012-05-30 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (en) * 2004-11-02 2009-07-29 浙江欧美环境工程有限公司 Turning type electric desalinization device
BRPI0615026A8 (en) 2005-08-19 2018-03-06 Abbott Lab double variable domain immunoglobulin and its uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX2008004693A (en) * 2005-10-21 2008-09-03 Catalyst Biosciences Inc Modified proteases that inhibit complement activation.
NZ571791A (en) * 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
CA2685714C (en) 2007-05-31 2016-04-12 University Of Washington Inducible mutagenesis of target genes
WO2010054403A1 (en) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110002931A1 (en) * 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
KR102184713B1 (en) * 2009-07-17 2020-12-01 오메로스 코포레이션 Masp isoforms as inhibitors of complement activation
CN102781471B (en) * 2009-10-16 2016-10-12 奥默罗斯公司 Method by suppression MASP-2 dependent complement activation treatment disseminated inravascular coagulation
AU2011222883B2 (en) * 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
RU2662563C2 (en) * 2011-04-08 2018-07-26 Юниверсити Оф Лестер Methods for treating conditions associated with masp-2 dependent complement activation
ES2670668T3 (en) * 2012-04-06 2018-05-31 Omeros Corporation Compositions and methods to inhibit MASP-1 and / or MASP-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Also Published As

Publication number Publication date
PL2861246T3 (en) 2021-10-25
IL261436B (en) 2021-08-31
KR20200116164A (en) 2020-10-08
PT2861246T (en) 2021-04-05
ES2864857T3 (en) 2021-10-14
EP2861246B1 (en) 2021-01-20
CN109908352A (en) 2019-06-21
EP4119577A2 (en) 2023-01-18
EP4119577A3 (en) 2023-11-08
US20220259325A1 (en) 2022-08-18
CL2014003455A1 (en) 2015-04-10
JP6771531B2 (en) 2020-10-21
US20190127484A1 (en) 2019-05-02
KR102339315B1 (en) 2021-12-15
EP3878865A3 (en) 2021-12-08
SI2861246T1 (en) 2021-08-31
AU2020202999A1 (en) 2020-05-28
HK1209623A1 (en) 2016-04-08
WO2013192240A3 (en) 2014-07-03
CA2875567C (en) 2023-11-14
IN2015KN00015A (en) 2015-07-31
KR20200015952A (en) 2020-02-13
IL236327A0 (en) 2015-02-26
NZ728179A (en) 2021-12-24
RU2015101230A (en) 2016-08-10
KR20150031298A (en) 2015-03-23
NZ629473A (en) 2017-02-24
RU2709351C2 (en) 2019-12-17
CA2875567A1 (en) 2013-12-27
MX2019012909A (en) 2020-12-10
JP6445972B2 (en) 2018-12-26
AU2018204285B2 (en) 2020-02-27
MX2020005700A (en) 2020-09-25
EP2861246A2 (en) 2015-04-22
IL236327B (en) 2019-02-28
BR112014031522A2 (en) 2017-08-01
CL2016003297A1 (en) 2017-06-02
CA3214532A1 (en) 2013-12-27
DK2861246T3 (en) 2021-04-26
EP2861246A4 (en) 2016-03-23
JP2021006546A (en) 2021-01-21
AU2013277309A1 (en) 2015-01-22
RS61755B1 (en) 2021-05-31
JP2019048881A (en) 2019-03-28
EP3878865A2 (en) 2021-09-15
KR20220100997A (en) 2022-07-18
HRP20210559T1 (en) 2021-05-14
RU2019140356A (en) 2020-01-27
LT2861246T (en) 2021-04-26
CN104717975A (en) 2015-06-17
HUE053727T2 (en) 2021-07-28
EP3058951A1 (en) 2016-08-24
WO2013192240A2 (en) 2013-12-27
ZA201500094B (en) 2019-08-28
US20130344073A1 (en) 2013-12-26
AU2013277309B2 (en) 2018-03-29
AU2020202999B2 (en) 2022-03-24
CN115040653A (en) 2022-09-13
JP2015521623A (en) 2015-07-30
IL261436A (en) 2018-11-04
CY1124234T1 (en) 2022-05-27
JP2022084946A (en) 2022-06-07

Similar Documents

Publication Publication Date Title
MX2020005700A (en) Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders.
MX2019004616A (en) Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors.
MX2016014634A (en) Compounds for treating ophthalmic diseases and disorders.
CY1119420T1 (en) NEW THERAPEUTIC APPROACHES TO PARKINSON'S DISEASE TREATMENT
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
UA113165C2 (en) APPLICATION OF A COMBINATION OF Baclofen AND ACOMPROSAT FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND A COMPOSITION CONTAINING Baclofen AND ACAMPROSAT
WO2013061161A3 (en) New combination therapies for treating neurological disorders
EA201200686A1 (en) NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BR112015001847A2 (en) compositions and treatment for eye diseases and disorders
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201300471A1 (en) SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2017006938A (en) Combination therapy for treatment of cancer.
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
NZ629675A (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
EA201590726A1 (en) LACHINIMOD TO REDUCE TALAMIC DAMAGE AT MULTIPLE SCLEROSIS
MX2021006985A (en) Methods for the treatment of depression.
MX2014005209A (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent.
CY1116234T1 (en) Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2 / 3 conformers
EA201790563A8 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
CY1116158T1 (en) Substituted 2-oxo- and 2-thiooxy-dihydroquinoline-3-carboxamides as KCNQ2 / 3 modulators
MX343366B (en) Nd2 peptides and methods of treating neurological disease.
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2014011843A (en) Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma.